Released: 23/12/2009

 
Click for Link:
http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20091223:nRSW6686Ea
RNS Number : 6686E
Intercytex Group plc
23 December 2009
 
 
23 December 2009
Intercytex Group plc - result of General Meeting
Intercytex Group plc (AIM: ICX) ("Intercytex") confirms that at the General Meeting held earlier today, all the
Resolutions, set out in the circular sent to shareholders on 7 December 2009, were duly passed. Cancellation of admission
to trading on AIM is therefore expected to occur at 7.00 a.m. on 8th January 2010. The Company's name will also be changed
to Regenerative Medicine Assets Limited. In addition, as set out in the circular, Dr Paul Kemp and Dr Alan Suggett have
resigned as directors of Intercytex, The Board wishes to thank both Alan and Paul for their contributions to the Company.
- Ends -
Enquiries
For more information, contact: 
 
 Intercytex Group plc                                       
 Nick Higgins, Chief Executive Officer  Tel: 0161 904 4500  
 Max Herrmann, Chief Financial Officer                      
                                                            
 Financial Dynamics                                         
 Jonathan Birt                          Tel: 0207 269 7205  
                                                            
 Piper Jaffray Ltd                                          
 Neil MackisonGraeme Smethurst          Tel: 0203 142 8700  
 
 
Intercytex' shares are listed on the Alternative Investment Market of the London Stock Exchange under the ticker symbol
ICX.L.
Additional information on the Company can be found at www.intercytex.com
Statements contained within this press release may contain forward-looking information or statements with respect to the
financial condition, results of operations and business achievements/performance of Intercytex and certain of the plans and
objectives of management of Intercytex with respect thereto. By their nature, forward-looking statements involve risks and
uncertainties that may cause actual results to vary from those contained in the forward-looking statements. In some cases,
you can identify such forward-looking statements by terminology such as 'may', 'will', 'could', 'forecasts', 'expects',
'plans', 'anticipates', 'believes', 'estimates', 'predicts', 'potential', 'continue' or similar expressions.  A number of
factors, including the satisfactory progress of research and development, could cause Intercytex' actual financial
condition, results of operations and business achievements/performance to differ materially from the estimates made or
implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements. Forward
projections reflect management's best estimates based on information available at the time of issue and are not a guarantee
of future performance. Other than as required by applicable law, Intercytex does not undertake any obligation to update or
revise any forward-looking information or statements to reflect events or circumstances after the date of this release.
The term "Intercytex" refers to Intercytex Group plc and its subsidiary undertakings.
This information is provided by RNS
The company news service from the London Stock Exchange